The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases
SV Retnakumar, C Chauvin, J Bayry - Pharmacology & Therapeutics, 2023 - Elsevier
The phenomenon of 'T cell exhaustion', a state of T cell dysfunction observed during chronic
infections and cancers, has been a major obstacle in mounting appropriate immune …
infections and cancers, has been a major obstacle in mounting appropriate immune …
[HTML][HTML] Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events
H Läubli, C Balmelli, L Kaufmann, M Stanczak… - … for immunotherapy of …, 2018 - Springer
Background Immune checkpoint inhibiting antibodies were introduced into routine clinical
practice for cancer patients. Checkpoint blockade has led to durable remissions in some …
practice for cancer patients. Checkpoint blockade has led to durable remissions in some …
[HTML][HTML] Infectious complications and immunotherapy: old pitfalls and new horizons
A Lasagna, I Cassaniti, P Sacchi, F Baldanti… - Future …, 2022 - Future Medicine
Activation of the PD-L1 signaling pathway is a key event in the tumor immune escape
mechanism that results in a consequent negative regulation of the apoptotic T cell-mediated …
mechanism that results in a consequent negative regulation of the apoptotic T cell-mediated …
Immune checkpoints and their inhibition in cancer and infectious diseases
The development of chronic infections and cancer is facilitated by a variety of immune
subversion mechanisms, such as the production of anti‐inflammatory cytokines, induction of …
subversion mechanisms, such as the production of anti‐inflammatory cytokines, induction of …
[HTML][HTML] Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study
Q Mei, G Hu, Y Yang, B Liu, J Yin, M Li… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Anti-COVID-19 vaccination may have functional implications for immune checkpoint inhibitor
treatment in patients with cancer. This study was undertaken to determine whether the safety …
treatment in patients with cancer. This study was undertaken to determine whether the safety …
[HTML][HTML] The role of the programmed cell death protein-1/programmed death-ligand 1 pathway, regulatory T cells and T helper 17 cells in tumor immunity: a narrative …
L Zhang, M Zhang, J Xu, S Li, Y Chen… - Annals of …, 2020 - ncbi.nlm.nih.gov
Tumor immunotherapy, especially that involving programmed cell death protein-1 (PD-
1)/programmed death-ligand 1 (PD-L1) immunosuppressive checkpoint inhibitors, has …
1)/programmed death-ligand 1 (PD-L1) immunosuppressive checkpoint inhibitors, has …
[HTML][HTML] Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets
HF Tsai, PN Hsu - Journal of biomedical science, 2017 - Springer
Immune checkpoints or coinhibitory receptors, such as cytotoxic T lymphocyte antigen
(CTLA)-4 and programmed death (PD)-1, play important roles in regulating T cell responses …
(CTLA)-4 and programmed death (PD)-1, play important roles in regulating T cell responses …
[HTML][HTML] Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and …
GM Weir, O Hrytsenko, T Quinton, NL Berinstein… - … for immunotherapy of …, 2016 - Springer
Background Future cancer immunotherapies will combine multiple treatments to generate
functional immune responses to cancer antigens through synergistic, multi-modal …
functional immune responses to cancer antigens through synergistic, multi-modal …
[HTML][HTML] Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L) 1
K Mortezaee, J Majidpoor - Biomedicine & Pharmacotherapy, 2023 - Elsevier
CD8+ T cells are the front-line defensive cells against cancer. Reduced infiltration and
effector function of CD8+ T cells occurs in cancer and is contributed to defective immunity …
effector function of CD8+ T cells occurs in cancer and is contributed to defective immunity …
Reinvigorating exhausted T cells by blockade of the PD-1 pathway
ABSTRACT T-cell exhaustion due to persistent antigen stimulation is a key feature of chronic
viral infections and cancer. Programmed cell death-1 (PD-1) is a major regulator of T-cell …
viral infections and cancer. Programmed cell death-1 (PD-1) is a major regulator of T-cell …